A Pilot Study of Potassium Supplementation for Adult Patients With Rheumatoid Arthritis - Full Text View

Sponsored by:	Shaheed Beheshti Medical University
Information provided by:	Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:	NCT00461448

Purpose

Rheumatoid arthritis is the paradigmatic immune-mediated inflammatory arthropathy. With respect to rheumatoid arthritis (RA), patients have been described as having inappropriately low spontaneous and stimulated cortisol secretion levels. Serum cortisol levels are decreased in RA patients who are taking prednisolone. Also, in patients RA, of longer duration, glucocorticoid receptor (GR) down-regulation has been reported without any change in cortisol levels. There is a reduced capacity for local reactivation of cortisone to cortisol in RA synovial cells. It is noteworthy that since synthetic glucocorticoids also use same reactivation shuttle (the cortisol-cortisone shuttle), the results also apply to therapeutic glucocorticoids.

Glucocorticoids are widely used to treat chronic inflammatory conditions including rheumatoid arthritis. Prednisolone has a greater effect than non-steroidal, anti-inflammatory drugs on joint tenderness and pain, whereas the difference in grip strength was not significant. There are no qualitative differences between the effects of endogenous cortisol and exogenously applied synthetic glucocorticoids, since all effects are transmitted via the same receptor. Cortisol, on the other hand, plays a major role in normal potassium homeostasis.

Recent studies have highlighted a role for diet, with suggestions that diets high in caffeine, low in antioxidants and high in red meat may contribute to an increased risk for the development of rheumatoid arthritis. Higher intakes of complex carbohydrates, dietary fiber, magnesium, folic acid, vitamin C and E, carotenoids and other phytochemicals have been shown to offer distinct advantages compared to diets containing meat and other foods of animal origin. The relation of a potassium deficiency to RA is much less well documented. The first person to definitively link potassium with arthritis was DeCoti Marsh in a book which purports to have numerous case histories using potassium associated with a veritable pot pourri of anions. LaCelle, Morgan & Atwater found that the cells of 50 arthritic patients were 30 to 50% lower than healthy people.

Our current clinical trial (clinical trial no NCT00399282) shows that most of patients with RA do not have enough potassium intake. This condition may contribute to a subclinical lower serum cortisol, although there is possibility that cortisol serum levels might be unchanged due to a sufficient "cortisol homeostasis" and "potassium homeostasis".

Condition	Intervention	Phase
Rheumatoid Arthritis	Drug: Potassium supplement	Phase I

MedlinePlus related topics: Dietary Supplements Rheumatoid Arthritis

Drug Information available for: Potassium chloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Supportive Care, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Pilot Study of Potassium Supplementation in the Treatment of Rheumatoid Arthritis: a 4-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Further study details as provided by Shaheed Beheshti Medical University:

Primary Outcome Measures:

Patient’s dietary and supplement potassium intake (combined technique: food frequency questionnaire, 24 hour food-recall, food record) [ Time Frame: within the 28 days (plus or minus 2 days) ]
Disease Activity Score (DAS28, 28-joint count) at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]
Patient’s global assessment of disease activity (0 to 10 cm visual analog scale: 0, symptom free; 10, very severe) at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]
Patient’s visual analogue scale (VAS) for pain at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]
Duration of morning stiffness (in minutes) at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]
Joint pain intensity, on a visual analogue scale (VAS) for pain (0 = no pain to 100mm =severe pain) at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]
Onset of fatigue (in minutes) after walking at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]
Ritchie’s articular index for pain joints at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]
Right and left grip strength (in mmHg) measured with a sphygmomanometer cuff inflated to 20 mmHg at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]
Classification of functional status in RA according to revised criteria of the American College of Rheumatology at Patient’s global assessment of disease activity (0 to 10 cm visual analog scale: 0, symptom free; 10, very severe) at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]

Secondary Outcome Measures:

Serum cortisol, NA, K, ACTH, aldosterone, creatinine, urea, uric acid, pH; urinalysis (urea, uric acid, Na, K, pH, creatinine), CRP, RF, and ESR at d 0, 28 [ Time Frame: within the first 28 days (plus or minus 2 days) ]

Enrollment:	32
Study Start Date:	February 2007
Study Completion Date:	April 2007

Detailed Description:

This study examines the hypothesis if patients with rheumatoid arthritis evaluate, or rate, symptom improvements after potassium supplementation (as KCl).

Participants will undergo the following tests and procedures:

Medical history and physical examination. Measurements of weight and height. Blood sample collections for clinical and research purposes. Quality of life questionnaires.

We therefore examined the hypothesis that examines effect of an orally administrated grape juice enriched (GJE) with 6000 mg potassium (as KCl) compared with that of a placebo grape juice (PGJ) on serum indices (cortisol, ACTH, aldosterone, creatinine, pH, Na, K), urinalysis (urea, uric acid, K, Na, creatinine, pH), GFR corrected by body surface area, ESR, CRP, RF, pain, quality of life, and disease activity in a case-controlled double-blind protocol in patients with RA with an established low dietary potassium intake to further investigate endogenous cortisol secretion and consequent possible relief.

Clinical (like Disease Activity, Pain) variables, along with the Quality of Life, and Biochemical Indices will be compared in two groups of patients after 28 days of oral GJE and PJE administration.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age 18 years or older
Diagnosis of RA, as defined by fulfilling at least four of seven American College of Rheumatology (ACR) criteria
Onset of arthritis after the age of 16 years
Positive for rheumatoid factor (RF)
Active RA, as defined by at least four swollen joints, at least four tender joints, and either an erythrocyte sedimentation rate (ESR) of greater than 30 mm/hr OR C-reactive protein level greater than 1.0 mg/dl (normal less than 0.4)
Willing to follow the study protocol
Willing to intake PGJ or EGJ
On a salt-restricted diet

Exclusion Criteria:

Abnormal kidney (including kidney stones in the 5 years prior to study entry or creatinine clearance less than 50 ml/min/1.73 m2 of body surface area) or liver disease
Currently taking medications that might affect potassium
Intra-articular injections within 4 weeks prior to study entry
Current peptic ulcer disease
History of alcohol or substance abuse
Active infection, or chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., HIV, hepatitis B virus, hepatitis C virus, tuberculosis [TB])
Known coronary artery disease or significant cardiac arrhythmias or severe congestive heart failure (New York Heart Association [NYHA] classes III or IV)
Definitive diagnosis of another autoimmune rheumatologic disease (e.g., systemic lupus erythematosus [SLE], scleroderma, primary Sjogren's syndrome, primary vasculitis)
History of cancer. Participants with previous resected basal or squamous cell carcinoma, treated cervical dysplasia, or treated in situ Grade I cervical cancer within 5 years prior to study entry are not excluded.
Any condition or treatment (including biologic therapies) that, in the opinion of the investigator, may place the participant at unacceptable risk during the study
Pregnancy
Vegetarian
Use of estrogen replacement therapy
Current use of diuretics, beta-blockers, anabolic drugs (steroids or other), angiotensin converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs), etc, or any drug (s) other than drugs indicated for the purpose of RA therapy which is (are) known to effect serum potassium levels
Hyperparathyroidism
Untreated thyroid disease
Significant immune disorder
Adrenal insufficiency, primary aldosteronism, or Bartter’s syndrome
Diabetes mellitus

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00461448

Locations

Iran, Islamic Republic of, East Azerbaidjan
Division of Rheumatoloy, Sina Teaching Hospital, Tabriz Medical Sciences University
Tabriz, East Azerbaidjan, Iran, Islamic Republic of
Sheikh-ol-Raees Ultra Specialized Clinic
Tabriz, East Azerbaidjan, Iran, Islamic Republic of

Sponsors and Collaborators

Shaheed Beheshti Medical University

Investigators

Study Chair:

Reza Rastmanesh, Ph.D.

National Nutrition and Food Sciences Technology Institute

More Information

Related Info This link exits the ClinicalTrials.gov site

Publications:

Weber CE. Copper response to rheumatoid arthritis. Med Hypotheses. 1984 Dec;15(4):333-48. Review.

Weber CE. Corticosteroid regulation of electrolytes. J Theor Biol. 1983 Oct 7;104(3):443-9.

Weber CE. A proposal for an experiment of potassium on rheumatoid arthritis. Clin Exp Rheumatol. 1983 Apr-Jun;1(2):184-6. No abstract available.

Study ID Numbers:	NNFTRI-B2484
Study First Received:	April 17, 2007
Last Updated:	April 27, 2007
ClinicalTrials.gov Identifier:	NCT00461448
Health Authority:	Iran: Ministry of Health

Keywords provided by Shaheed Beheshti Medical University:

Potassium supplement
Rheumatoid Arthritis
Pain
Disease Activity

Study placed in the following topic categories:

Autoimmune Diseases
Musculoskeletal Diseases
Joint Diseases
Arthritis

Connective Tissue Diseases
Arthritis, Rheumatoid
Pain
Rheumatic Diseases

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009